<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143480</url>
  </required_header>
  <id_info>
    <org_study_id>100129</org_study_id>
    <secondary_id>10-E-0129</secondary_id>
    <nct_id>NCT01143480</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Innate on the Inflammatory Response to Endotoxin</brief_title>
  <official_title>Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Innate immunity is the process by which white blood cells and other parts of the immune&#xD;
      system sense and respond to potential infections by causing an inflammation. Researchers are&#xD;
      interested in studying how the body responds to certain environmental factors, and whether&#xD;
      the body s response can contribute to chronic illnesses or diseases such as asthma and&#xD;
      certain types of cancers.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To examine how specific genes and proteins in blood cells respond to environmental&#xD;
      exposures.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Healthy volunteers between 18 and 45 years of age.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  The study will involve one visit of 45 to 60 minutes.&#xD;
&#xD;
        -  Participants will be screened with a brief physical examination and finger stick to&#xD;
           determine if they are eligible to donate blood for the study, and will complete a&#xD;
           questionnaire about any medications or other drugs (e.g., cigarettes) they may be&#xD;
           taking.&#xD;
&#xD;
        -  Participants will provide a blood sample for research purposes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study will examine the role of innate immunity on the Inflammatory response of&#xD;
      monocytes and macrophages to endotoxin. Approximately 1450 healthy participants aged 18 years&#xD;
      and older will be identified and recruited from the Environmental Polymorphism Registry&#xD;
      (EPR). The EPR is a long-term project to collect and store up to 15,000 DNA samples for use&#xD;
      in research studies from individuals in the greater North Carolina Triangle Region. It is&#xD;
      anticipated that approximately 50% of the participants contacted will enroll and about 15% of&#xD;
      participants enrolled will withdraw.&#xD;
&#xD;
      This controlled, observational gene association study will recruit participants on the basis&#xD;
      of genotype and then observe the phenotype of each participant. There are several SNPs of&#xD;
      interest in the genes TIRAP, MyD88, ABCA1, CD14, CD44, ITIH3, ITIH4, TLR4, TNFa, TLR5. IRGM&#xD;
      and APOL1. In addition there are alleles of interest in the gene ApoE. These alleles taken&#xD;
      together are considered a polymorphism. For each polymorphism of interest a separate group of&#xD;
      participants will be recruited (including heterozygous and homozygous for both the minor and&#xD;
      major alleles for each SNP). A maximum of 200 mLs of blood will be obtained from each&#xD;
      participant during one visit lasting approximately 1.5 hours. Blood monocytes will be&#xD;
      isolated from the donated blood samples and cultured to obtain macrophages. The macrophages&#xD;
      will be exposed ex vivo to an endotoxin (LPS) and to PAM3CSK4 to determine cell response&#xD;
      depending on genotype. In studies of APOL1, a urine specimen will also be collected to&#xD;
      evaluate for protein filtration.&#xD;
&#xD;
      The primary objective is to determine associations between select polymorphisms in genes&#xD;
      [TIRAP (TIR Associated Protein), MyD88 (Myeloid Differentiation Primary Response Protein 88),&#xD;
      ApoE (Apolipoprotein E), ABCA1 (ATP Binding Cassette Transporter A1), CD14, CD44, ITIH3,&#xD;
      ITIH4, TLR4, TNFa, TLR5, IRGM and APOL1] and quantitative in vitro inflammatory functions of&#xD;
      two cell types, the macrophage and neutrophil. The primary endpoints of this study for both&#xD;
      cell types will be levels of 6 cytokines TNF alpha, IL-6, MIP-2, IL-8, MCP-1, and IFN-beta&#xD;
      (ELISA) induced by LPS and by PAM3CSK4 plus baseline cytokine levels (no exposure to LPS or&#xD;
      PAM3CSK4). Urinary levels of protein will be quantified in some studies as a measure of early&#xD;
      kidney&#xD;
&#xD;
      dysfunction.&#xD;
&#xD;
      We hope the results of this study may lead to discovery of important information regarding&#xD;
      the role of MDC1 (Mediator of DNA damage Checkpoint protein 1) in human disease, potentially&#xD;
      identifying new targets for future studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2012</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoints of this study are for both cell types and will be levels of 6 cytokines [TNF alpha, IL-6, MIP-2, IL-8, MCP-1, and IFN-beta (ELISA)] induced by LPS and by PAM3CSK4 plus baseline cytokine levels (no exposure to LPS or PAM3...</measure>
    <time_frame>After analysis</time_frame>
    <description>The primary endpoints of this study are for both cell types and will be levels of 6 cytokines [TNF alpha, IL-6, MIP-2, IL-8, MCP-1, and IFN-beta (ELISA)] induced by LPS and by PAM3CSK4 plus baseline cytokine levels (no exposure to LPS or PAM3CSK4).</description>
  </primary_outcome>
  <number_of_groups>13</number_of_groups>
  <enrollment type="Anticipated">725</enrollment>
  <condition>Asthma</condition>
  <condition>Atherosclerosis</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>ABCA1</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APOE</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APOL1</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD14</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD44</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IRGM</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITIH3</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITIH4</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MyD88</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIRAP</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLR4</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TLR5</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNFa</arm_group_label>
    <description>SNP or allele of interest</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants enrolled in Environmental Polymorphism Registry (EPR)@@@&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Male or female 18 years of age or older&#xD;
&#xD;
          -  Participants must be able to understand and provide written informed consent to&#xD;
             participate in the study&#xD;
&#xD;
          -  Participants must be able to travel to the CRU&#xD;
&#xD;
          -  Willing and able to fast after midnight the night prior to their study appointment&#xD;
&#xD;
          -  Healthy participants as defined by the International Red Cross guidelines (Healthy&#xD;
             means that an individual feels well and can perform normal activities. If the&#xD;
             individual has a chronic condition such as diabetes or high blood pressure, healthy&#xD;
             also means that they are being treated and the condition is under control).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Use of nonsteriodal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment&#xD;
             visit (e.g., Motrin, ibuprofen, naproxen, and Advil)&#xD;
&#xD;
          -  Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit&#xD;
&#xD;
          -  Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit&#xD;
             (e.g., Zocor, Mevacor, Lipitor, and Crestor)&#xD;
&#xD;
          -  Use of immunosuppressants or other immune-modifying drugs [e.g., Rituxan, Humira,&#xD;
             Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)],&#xD;
             Monoclonal antibodies [e.g., infliximab (Remicade)], and corticosteroids (e.g.,&#xD;
             prednisone, prednisolone and dexamethasone)&#xD;
&#xD;
          -  Current treatment for cancer with chemotherapy or radiation&#xD;
&#xD;
          -  Confirmed or suspected immunosuppressive or immunodeficient condition&#xD;
&#xD;
          -  GI or respiratory Illness within 5 days prior to enrollment visit, including cold or&#xD;
             allergies&#xD;
&#xD;
          -  Smoked tobacco, chewed tobacco or used electronic cigarettes within 2 weeks prior to&#xD;
             enrollment visit (for participants who provide a urine specimen, this will be defined&#xD;
             by urine cotinine &gt;200 ng/mL at visit)&#xD;
&#xD;
          -  Alcohol consumption greater than 2 standard drinks (1 standard drink contains 15 g of&#xD;
             ethanol) per day within the last 24 hours prior to the enrollment visit&#xD;
&#xD;
          -  Body weight &lt; 50 kg (&lt;110 lbs)&#xD;
&#xD;
          -  Temperature &gt; 37.6 C; blood pressure &lt; 90/50 mm Hg or &gt; 170/95 mm Hg; pulse rate &lt; 50&#xD;
             or &gt;100 beats/minute&#xD;
&#xD;
          -  Pregnant or suspected pregnancy&#xD;
&#xD;
          -  Chronic Kidney Disease&#xD;
&#xD;
        The PI may review medication use on a case by case basis and make a medical determination&#xD;
        on the participant s eligibility. In these cases, the PI determination will be documented&#xD;
        in the participant s chart.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael B Fessler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Environmental Health Sciences (NIEHS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NIEHS Join A Study Recruitment Group</last_name>
    <phone>(855) 696-4347</phone>
    <email>myniehs@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael B Fessler, M.D.</last_name>
    <phone>(984) 287-4081</phone>
    <email>fesslerm@niehs.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NIEHS Clinical Research Unit (CRU)</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Murphy</last_name>
      <phone>919-541-9839</phone>
      <email>murphylb@mail.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2010-E-0129.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Castiblanco J, Varela DC, Castaño-Rodríguez N, Rojas-Villarraga A, Hincapié ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol. 2008 Sep;8(5):541-4. doi: 10.1016/j.meegid.2008.03.001. Epub 2008 Mar 12.</citation>
    <PMID>18417424</PMID>
  </reference>
  <reference>
    <citation>Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1322-32. Epub 2003 May 22. Review.</citation>
    <PMID>12763760</PMID>
  </reference>
  <reference>
    <citation>Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine. 2008 Sep;43(3):342-9. doi: 10.1016/j.cyto.2008.07.010. Epub 2008 Aug 15. Review.</citation>
    <PMID>18706831</PMID>
  </reference>
  <verification_date>October 12, 2021</verification_date>
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endotoxin</keyword>
  <keyword>Innate Immunity</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

